Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts

Patrick Tarwater, John Mellors, Mary E. Gore, Joseph Bernard Margolick, John Phair, Roger Detels, Alvaro Munoz

Research output: Contribution to journalArticle

Abstract

Two methods are presented for measuring population effectiveness (i.e., reduction of disease in a population in which only some receive treatment) of antiretroviral therapy among human immunodeficiency virus (HIV)-infected men at risk for acquired immunodeficiency syndrome (AIDS) and followed between January 1, 1986, and June 30, 1999, in the Multicenter AIDS Cohort Study. Method I, requiring use of a seroincident cohort, estimates relative hazards of AIDS for persons at equal duration of infection. Method II, allowing use of a seroprevalent cohort, estimates relative hazards since the beginning of therapy eras for persons starting at equal levels of prognostic markers of disease stage (CD4 cell count and HIV type 1 RNA). The follow-up interval was divided into four calendar periods to characterize different eras of antiretroviral therapy. For method I, the relative hazards were 1.52 (95% confidence interval (CI): 0.93, 2.49), 0.91 (95% CI: 0.66, 1.26), and 0.30 (95% CI: 0.18, 0.51) for the eras of no therapy, dual nucleoside therapy, and potent combination antiretroviral therapy, respectively (monotherapy was the reference era). For method II, the corresponding relative hazards were 1.52 (95% CI: 1.10, 2.09), 1.03 (95% CI: 0.77, 1.38), and 0.31 (95% CI: 0.21, 0.45). These results extend the measurement of population effectiveness from incident to prevalent cohorts and demonstrate the ability of cohort studies to complement information provided by clinical trials.

Original languageEnglish (US)
Pages (from-to)675-681
Number of pages7
JournalAmerican Journal of Epidemiology
Volume154
Issue number7
DOIs
StatePublished - Oct 1 2001

Fingerprint

HIV
Confidence Intervals
Population
Acquired Immunodeficiency Syndrome
Therapeutics
Cohort Studies
CD4 Lymphocyte Count
Nucleosides
HIV-1
Clinical Trials
RNA
Infection

Keywords

  • Acquired immunodeficiency syndrome
  • Cohort studies
  • Epidemiologic methods
  • HIV

ASJC Scopus subject areas

  • Epidemiology

Cite this

Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts. / Tarwater, Patrick; Mellors, John; Gore, Mary E.; Margolick, Joseph Bernard; Phair, John; Detels, Roger; Munoz, Alvaro.

In: American Journal of Epidemiology, Vol. 154, No. 7, 01.10.2001, p. 675-681.

Research output: Contribution to journalArticle

@article{e9fe6bf2dc404d85a960e089c15550b0,
title = "Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts",
abstract = "Two methods are presented for measuring population effectiveness (i.e., reduction of disease in a population in which only some receive treatment) of antiretroviral therapy among human immunodeficiency virus (HIV)-infected men at risk for acquired immunodeficiency syndrome (AIDS) and followed between January 1, 1986, and June 30, 1999, in the Multicenter AIDS Cohort Study. Method I, requiring use of a seroincident cohort, estimates relative hazards of AIDS for persons at equal duration of infection. Method II, allowing use of a seroprevalent cohort, estimates relative hazards since the beginning of therapy eras for persons starting at equal levels of prognostic markers of disease stage (CD4 cell count and HIV type 1 RNA). The follow-up interval was divided into four calendar periods to characterize different eras of antiretroviral therapy. For method I, the relative hazards were 1.52 (95{\%} confidence interval (CI): 0.93, 2.49), 0.91 (95{\%} CI: 0.66, 1.26), and 0.30 (95{\%} CI: 0.18, 0.51) for the eras of no therapy, dual nucleoside therapy, and potent combination antiretroviral therapy, respectively (monotherapy was the reference era). For method II, the corresponding relative hazards were 1.52 (95{\%} CI: 1.10, 2.09), 1.03 (95{\%} CI: 0.77, 1.38), and 0.31 (95{\%} CI: 0.21, 0.45). These results extend the measurement of population effectiveness from incident to prevalent cohorts and demonstrate the ability of cohort studies to complement information provided by clinical trials.",
keywords = "Acquired immunodeficiency syndrome, Cohort studies, Epidemiologic methods, HIV",
author = "Patrick Tarwater and John Mellors and Gore, {Mary E.} and Margolick, {Joseph Bernard} and John Phair and Roger Detels and Alvaro Munoz",
year = "2001",
month = "10",
day = "1",
doi = "10.1093/aje/154.7.675",
language = "English (US)",
volume = "154",
pages = "675--681",
journal = "American Journal of Epidemiology",
issn = "0002-9262",
publisher = "Oxford University Press",
number = "7",

}

TY - JOUR

T1 - Methods to assess population effectiveness of therapies in human immunodeficiency virus incident and prevalent cohorts

AU - Tarwater, Patrick

AU - Mellors, John

AU - Gore, Mary E.

AU - Margolick, Joseph Bernard

AU - Phair, John

AU - Detels, Roger

AU - Munoz, Alvaro

PY - 2001/10/1

Y1 - 2001/10/1

N2 - Two methods are presented for measuring population effectiveness (i.e., reduction of disease in a population in which only some receive treatment) of antiretroviral therapy among human immunodeficiency virus (HIV)-infected men at risk for acquired immunodeficiency syndrome (AIDS) and followed between January 1, 1986, and June 30, 1999, in the Multicenter AIDS Cohort Study. Method I, requiring use of a seroincident cohort, estimates relative hazards of AIDS for persons at equal duration of infection. Method II, allowing use of a seroprevalent cohort, estimates relative hazards since the beginning of therapy eras for persons starting at equal levels of prognostic markers of disease stage (CD4 cell count and HIV type 1 RNA). The follow-up interval was divided into four calendar periods to characterize different eras of antiretroviral therapy. For method I, the relative hazards were 1.52 (95% confidence interval (CI): 0.93, 2.49), 0.91 (95% CI: 0.66, 1.26), and 0.30 (95% CI: 0.18, 0.51) for the eras of no therapy, dual nucleoside therapy, and potent combination antiretroviral therapy, respectively (monotherapy was the reference era). For method II, the corresponding relative hazards were 1.52 (95% CI: 1.10, 2.09), 1.03 (95% CI: 0.77, 1.38), and 0.31 (95% CI: 0.21, 0.45). These results extend the measurement of population effectiveness from incident to prevalent cohorts and demonstrate the ability of cohort studies to complement information provided by clinical trials.

AB - Two methods are presented for measuring population effectiveness (i.e., reduction of disease in a population in which only some receive treatment) of antiretroviral therapy among human immunodeficiency virus (HIV)-infected men at risk for acquired immunodeficiency syndrome (AIDS) and followed between January 1, 1986, and June 30, 1999, in the Multicenter AIDS Cohort Study. Method I, requiring use of a seroincident cohort, estimates relative hazards of AIDS for persons at equal duration of infection. Method II, allowing use of a seroprevalent cohort, estimates relative hazards since the beginning of therapy eras for persons starting at equal levels of prognostic markers of disease stage (CD4 cell count and HIV type 1 RNA). The follow-up interval was divided into four calendar periods to characterize different eras of antiretroviral therapy. For method I, the relative hazards were 1.52 (95% confidence interval (CI): 0.93, 2.49), 0.91 (95% CI: 0.66, 1.26), and 0.30 (95% CI: 0.18, 0.51) for the eras of no therapy, dual nucleoside therapy, and potent combination antiretroviral therapy, respectively (monotherapy was the reference era). For method II, the corresponding relative hazards were 1.52 (95% CI: 1.10, 2.09), 1.03 (95% CI: 0.77, 1.38), and 0.31 (95% CI: 0.21, 0.45). These results extend the measurement of population effectiveness from incident to prevalent cohorts and demonstrate the ability of cohort studies to complement information provided by clinical trials.

KW - Acquired immunodeficiency syndrome

KW - Cohort studies

KW - Epidemiologic methods

KW - HIV

UR - http://www.scopus.com/inward/record.url?scp=0035479131&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035479131&partnerID=8YFLogxK

U2 - 10.1093/aje/154.7.675

DO - 10.1093/aje/154.7.675

M3 - Article

C2 - 11581102

AN - SCOPUS:0035479131

VL - 154

SP - 675

EP - 681

JO - American Journal of Epidemiology

JF - American Journal of Epidemiology

SN - 0002-9262

IS - 7

ER -